NCT02636595View on ClinicalTrials.gov

The Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 4, 5, or 6 Infection (ENDURANCE-4)

PHASE3CompletedINTERVENTIONAL
Enrollment

121

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

October 31, 2016

Study Completion Date

January 31, 2017

Conditions
Hepatitis C Virus
Interventions
DRUG

ABT-493/ABT-530

Tablet; ABT-493 coformulated with ABT-530

Sponsors

Lead Sponsor

AbbVie
All Listed Sponsors
lead

AbbVie

INDUSTRY